Stage 1: History & Presentation (Timestamp: 2 Weeks Prior to Admission)
A 31-year-old primigravida at 22 weeks gestation (residing in Delhi NCR, no prior medical/surgical history except migraines) presents to the emergency department for labor induction following intrauterine fetal demise (IUFD).
HPI:
- 2 Weeks Ago: Developed dysuria, urinary frequency, dark urine, and intermittent non-bloody watery diarrhea. Evaluated by her obstetrician and treated with Ceftriaxone for suspected UTI.
- Presenting Event: Routine obstetric ultrasound revealed absence of fetal heart motion (intrauterine fetal demise), prompting urgent emergency admission for labor induction.
- ROS: Denies fevers, chills, night sweats, weight loss, chest pain, dyspnea, gross hematuria, rashes, or joint pain. Minimal post-delivery vaginal bleeding and mild lower abdominal cramping.
- Social & Family History: Married, non-smoker, no alcohol or drug use. No family history of autoimmune or bleeding disorders. G1P0.
Hello, Chief Resident here.
Key Findings: A 31-year-old primigravida at 22 weeks gestation presents with intrauterine fetal demise (IUFD) shortly after experiencing dark urine, dysuria, and watery diarrhea, treated empirically with ceftriaxone in an endemic region (Delhi NCR).
Differential Diagnoses:
1. Severe Systemic / Transplacental Infection (e.g., Listeria, Salmonella, Leptospirosis): 40% – Antecedent GI/GU prodrome leading to chorioamnionitis or fetal sepsis.
2. Viral Hepatitis (Hepatitis E): 25% – Endemic in India; manifests with GI symptoms and dark urine (choluria), carrying high maternal-fetal mortality.
3. Thrombotic Microangiopathy (TTP / HUS / HELLP) or APLA: 20% – Dark urine (hemoglobinuria) following GI prodrome, triggering placental infarction and fetal death.
4. Malaria (Falciparum): 15% – Endemic; can cause hemolysis/blackwater fever and severe fetal distress/loss.
Prioritized Diagnostic Tests:
1. CBC with Peripheral Smear: Evaluate for leukocytosis, thrombocytopenia, and schistocytes (hemolysis).
2. LFTs, RFTs, LDH, & Haptoglobin: Assess for acute liver failure, renal impairment, and microangiopathic hemolysis.
3. Urinalysis: Differentiate hematuria, hemoglobinuria, and bilirubinuria.
4. Blood/Urine Cultures & Fetal/Placental Histopathology: Identify underlying bacterial pathogens.
5. Serologies: Hepatitis E IgM, Malaria RDT/smear, and Leptospira IgM.
Hello Attending Consultant here
Critique: Solid endemic focus, but overweights infection without prioritizing hemolysis workup post-IUFD; omits coagulopathy screen and placental pathology urgency. Ceftriaxone may mask bacteremia—reassess timing.
Top 3 DDx:
1. HEV infection (endemic fulminant hepatitis with IUFD)
2. TMA/aHUS (GI prodrome → hemoglobinuria → placental thrombosis)
3. Leptospirosis (Weil’s: dark urine, diarrhea, fetal loss)
Specific points:
1. Add PT/INR, aPTT, fibrinogen, D-dimer for DIC/HELLP overlap.
2. Urgent HEV RNA/IgM + ALT/AST trend; avoid empiric abx delay.
3. Peripheral smear + ADAMTS13 activity now.
4. Malaria smear/RDT + G6PD before any primaquine consideration.
5. Placental histopathology + fetal autopsy mandatory.
6. Blood cultures ×2 prior to further antibiotics.
7. Renal ultrasound if Cr rises; monitor for postpartum TMA flare.
Hello, Expert Clinician here.
Best current unifying diagnosis: acute hepatitis E with pregnancy-associated hepatic dysfunction causing IUFD. Delhi residence, dark urine likely choluria, watery diarrhea/prodrome, and fetal demise fit; absence of fever/jaundice does not exclude HEV.
Top differentials:
- TMA/aHUS or HELLP/DIC: fits post-infectious hemoglobinuria and placental thrombosis, but needs thrombocytopenia, schistocytes, high LDH, renal injury, hypertension/coagulopathy.
- Leptospirosis/Weil disease: endemic, dark urine, diarrhea, fetal loss; ceftriaxone may partially treat and sterilize cultures, but lack of fever, myalgia, conjunctival suffusion, renal failure lowers probability.
- Malaria/sepsis: possible in Delhi, but afebrile course argues against.
Key pivot: prove whether “dark urine” was bilirubinuria versus hemoglobin/hematuria and whether there is hemolysis plus coagulopathy.
Next move: draw CBC/smear, AST/ALT/bilirubin, creatinine, LDH/haptoglobin, urinalysis, PT/INR/aPTT/fibrinogen/D-dimer, HEV IgM/RNA, leptospira PCR/serology, malaria smear, cultures before antibiotics; ADAMTS13 if schistocytes. Send placenta/fetus for pathology.
Pearl: in pregnancy, dark urine after a GI prodrome is hepatic/hemolytic until proven otherwise—not a simple UTI.
Stage 2: Physical Examination & Initial Emergency Evaluation (Timestamp: Admission / Day 1)
Physical Exam: T 38.3°C (febrile), HR 123 bpm (tachycardia), BP 141/80 mmHg (mild HTN), RR 18/min, SpO2 100% room air. Well-appearing, mild distress. Abdomen: Soft, non-tender, involuting uterus. Lungs: Clear. Skin: No purpura, petechiae, or jaundice. Neuro: Non-focal, alert and oriented (no encephalopathy or focal deficits).
Initial Laboratory Panel:
- Hemogram: WBC 12.4 x 10³/µL, Hb 10.9 g/dL, Profound Thrombocytopenia (Platelet Count 9,000/µL).
- Renal & Electrolyte Panel: Serum Creatinine 1.5 mg/dL (baseline 1.0 mg/dL, AKI Stage 1), BUN 37 mg/dL, Bicarbonate 17 mEq/L (non-anion gap metabolic acidosis).
- Hepatic Panel: AST 151 U/L, ALT 61 U/L, Total Bilirubin 1.4 mg/dL.
- Hemolysis & Coagulation Panel: Undetectable Haptoglobin (<10 mg/dL), Markedly Elevated LDH (1,616 U/L), Fibrinogen 356 mg/dL, PT/INR 0.9, aPTT 25.1 sec.
Hello, Chief Resident here.
Updated Key Findings: Febrile primigravida post-IUFD with microangiopathic hemolytic anemia (MAHA: LDH 1,616 U/L, haptoglobin <10 mg/dL), profound isolated thrombocytopenia (9,000/µL), mild AKI (Cr 1.5 mg/dL), and intact coagulation parameters.
Differential Diagnoses:
1. Thrombotic Thrombocytopenic Purpura (TTP): 50% – Profound thrombocytopenia (<30,000/µL), MAHA, and normal coags triggered by pregnancy/infection strongly point to TTP.
2. Complement-Mediated TMA / aHUS: 30% – Post-infectious GI prodrome, AKI, and MAHA with severe thrombocytopenia.
3. HELLP Syndrome: 15% – Mild HTN and transaminitis with MAHA/thrombocytopenia, though platelets <10,000/µL is unusually severe.
4. Infectious Sepsis (e.g., Leptospirosis, Malaria, HEV): 5% – Antecedent fever and GI symptoms, though normal coagulation makes primary DIC/sepsis less likely.
Prioritized Next Steps:
1. Peripheral Blood Smear: Quantify schistocytes.
2. STAT ADAMTS13 Activity & Inhibitor Assay: Draw immediately before blood products.
3. Immediate Therapeutic Plasma Exchange (TPE) Consultation: Emergency initiation for presumed life-threatening TTP.
4. Direct Antiglobulin Test (DAT/Coombs): Exclude autoimmune hemolysis.
5. Stool Shiga Toxin & Complement Panel: Evaluate alternative TMA etiologies.
Hello Attending Consultant here
Critique: Correctly elevates TTP given PLT <10k + MAHA + normal coags, but underweights infection-triggered TMA and postpartum timing; delays smear confirmation and ignores ongoing fever as potential driver. TPE urgency appropriate yet incomplete without concurrent infection exclusion.
Top 3 DDx:
1. Pregnancy-associated TTP (ADAMTS13 deficiency)
2. Complement-mediated aHUS (post-infectious/GI prodrome + AKI)
3. HELLP/TMA overlap or infection-triggered (HEV/lepto/malaria) MAHA
Specific points:
1. STAT peripheral smear for schistocyte quantification before any transfusion.
2. Draw ADAMTS13 activity/inhibitor + complement (C3/C4/CH50/AH50) pre-TPE.
3. Initiate emergent TPE + steroids; hold PLT transfusion unless bleeding.
4. Repeat blood/urine cultures + HEV RNA, leptospira PCR, malaria smear now.
5. Serial Cr/LDH/PLT q6h; add renal Doppler if AKI worsens.
6. DAT + direct Coombs to exclude AIHA; fibrinogen trend for occult DIC.
7. Placental pathology review mandatory for microvascular thrombosis.
Hello, Expert Clinician here.
Best current unifying diagnosis: pregnancy/postpartum TTP—immune-mediated severe ADAMTS13 deficiency—causing MAHA, profound thrombocytopenia, mild renal injury, and likely placental microvascular thrombosis with IUFD. Fever and infection can be triggers rather than the primary disease.
Top differentials:
- aHUS/complement TMA: fits GI prodrome, renal injury, MAHA; platelets around 9k are more classic for TTP, but overlap is real.
- HELLP/TMA: mild hypertension and AST/ALT elevation fit, yet normal INR/aPTT, very low platelets, and extremely high LDH favor TTP.
- Infection with secondary TMA (HEV, leptospirosis, malaria, sepsis): plausible endemic triggers; normal coagulation argues against primary DIC.
Key pivot: MAHA + platelet count ≈10k + relatively normal coagulation = TMA, with TTP leading until ADAMTS13 returns.
Next move: obtain smear/DAT and pre-treatment ADAMTS13 activity/inhibitor, then start emergent plasma exchange plus high-dose corticosteroids for presumed TTP; do not delay treatment awaiting results. Simultaneously send cultures and endemic infection testing; avoid platelet transfusion unless life-threatening bleeding.
Pearl: in postpartum MAHA, very severe thrombocytopenia with normal PT/aPTT should trigger TPE before diagnostic certainty.
Stage 3: Postpartum Longitudinal Workup (Hospital Days 1-2)
Laboratory & Diagnostic Trajectory:
- Hemogram: WBC 14.5 x 10³/µL, Hb dropped to 7.4 g/dL (severe anemia), Platelet Count 44,000/µL (after 2 units platelet transfusion).
- Renal Panel: Serum Creatinine 1.7 mg/dL, BUN 34 mg/dL.
- Hemolysis Workup: Reticulocyte Count 15.1% (marked reticulocytosis), Direct Antiglobulin Test (DAT / Coombs) Negative (confirming non-immune MAHA).
- Peripheral Blood Smear: Numerous Schistocytes (fragmented RBCs), polychromasia, ovalocytes, and immature granulocytes.
- Autoimmune & Serologic Panel: Anti-Cardiolipin & Beta-2 Glycoprotein I negative, Syphilis negative, Parvovirus B19 IgM negative (IgG positive), Blood cultures negative. Urine protein-to-creatinine ratio 3.4 g/g (proteinuria).
- Renal Ultrasound: Echogenic kidneys with mild fullness of right renal collecting system, small perisplenic fluid, no hydronephrosis.
Hello, Chief Resident here.
Updated Key Findings: Postpartum days 1–2 demonstrate progressive Coombs-negative MAHA with severe schistocytosis, high reticulocytosis (15.1%), worsening anemia (Hb 7.4 g/dL), mild AKI (Cr 1.7 mg/dL), and new nephrotic-range proteinuria (UPCR 3.4 g/g).
Differential Diagnoses:
1. Thrombotic Thrombocytopenic Purpura (TTP): 55% – Severe initial thrombocytopenia (<10k), MAHA, normal coags, and multiorgan involvement heavily point to severe ADAMTS13 deficiency.
2. Complement-Mediated TMA / aHUS: 35% – Antecedent GI/GU prodrome, worsening renal dysfunction, and heavy proteinuria suggest alternative complement pathway dysregulation.
3. Severe Postpartum HELLP / TMA Overlap: 10% – Less likely given persistence post-delivery and extreme initial thrombocytopenia, but warrants consideration.
Prioritized Next Steps:
1. Expedite ADAMTS13 Activity & Inhibitor Results: Essential for definitive distinction between TTP and aHUS.
2. Maintain Daily Therapeutic Plasma Exchange (TPE) + High-Dose Steroids: Consider adding Caplacizumab if immune TTP is confirmed.
3. Plan for Eculizumab/Ravulizumab: Initiate early if ADAMTS13 activity is >10% or if clinical response to TPE fails (aHUS).
4. Comprehensive Complement Panel: Draw C3, C4, CH50, Factor H/I, and anti-Factor H autoantibodies.
5. Strict Avoidance of Platelet Transfusions: Prevent fueling active microvascular thrombosis unless life-threatening hemorrhage occurs.
Hello Attending Consultant here
Critique: Appropriately prioritizes TTP vs aHUS bifurcation and TPE continuation, but over-relies on pending ADAMTS13 without addressing transfusion-driven PLT rise artifact, proteinuria etiology, or infection persistence; delays complement genetics and under-emphasizes smear quantification trends.
Top 3 DDx:
1. Pregnancy-associated TTP (severe ADAMTS13 deficiency)
2. Complement-mediated aHUS (GI prodrome + AKI/proteinuria)
3. Persistent infection-triggered TMA (HEV/lepto residual)
Specific points:
1. Quantify schistocyte % daily; trend LDH/Hb/PLT q6–8h post-TPE.
2. Confirm ADAMTS13 drawn pre-any plasma; add inhibitor titer STAT.
3. Full complement panel (C3/C4/AH50, anti-FH) + genetics if ADAMTS13 >10%.
4. Hold further PLT transfusions; reverse prior units’ confounding effect.
5. Repeat HEV RNA, leptospira PCR, malaria smear amid ongoing fever risk.
6. 24h urine protein + renal biopsy consideration if Cr/proteinuria worsen.
7. Add caplacizumab empirically if TTP phenotype dominates pending labs.
Hello, Expert Clinician here.
Best current unifying diagnosis: acquired thrombotic thrombocytopenic purpura (TTP), likely pregnancy-associated and possibly infection-triggered. DAT-negative MAHA with numerous schistocytes, profound thrombocytopenia, normal PT/aPTT, and postpartum persistence strongly support TMA; platelets near 10k particularly favor severe ADAMTS13 deficiency.
Top differentials:
- Complement-mediated aHUS: GI prodrome, AKI, and 3.4 g/g proteinuria fit well; renal-predominant TMA remains a close alternative.
- HELLP/postpartum TMA: possible, but persistence after delivery and extreme thrombocytopenia argue against uncomplicated HELLP.
- Infection-associated TMA/DIC: HEV, leptospirosis, malaria, or sepsis may trigger TMA, but normal coagulation and negative cultures make primary DIC less likely.
Key pivot: pre-plasma ADAMTS13 activity/inhibitor. <10% confirms TTP; preserved activity shifts toward aHUS. The post-transfusion platelet rise cannot be interpreted as treatment response.
Next move: continue daily plasma exchange plus corticosteroids without waiting for results; add caplacizumab if TTP phenotype dominates. If ADAMTS13 is preserved or response is poor, begin eculizumab after meningococcal protection. Avoid further platelet transfusion unless life-threatening bleeding.
Pearl: in TMA, platelet transfusion can both worsen thrombosis and falsely obscure disease trajectory.
Stage 4: Specialized Thrombotic Microangiopathy & Genetic Evaluation (Timestamp: Hospital Days 3-5)
Targeted TMA Evaluation & Emergency Management:
- Plasmic Score Calculation: Score = 6/7 (High Risk for TTP: Platelets <30k, hemolysis markers, no cancer/transplant, MCV 92 fL, INR <1.5, Cr <2.0).
- Emergency Intervention: Immediate daily Therapeutic Plasma Exchange (PEX) initiated + High-Dose Oral Corticosteroids (Prednisone 1 mg/kg/day).
- ADAMTS13 Assays:
- ADAMTS13 Activity Level: 6% (severely deficient, <10% confirms TTP).
- ADAMTS13 Inhibitor Antibody: Negative (<0.4 U/mL, ruling out Acquired Autoimmune TTP).
- Targeted Genetic Sequencing: Identified Biallelic Pathogenic Mutations (Compound Heterozygous / Homozygous) in the ADAMTS13 Gene, confirming Congenital / Hereditary TTP (Upshaw-Schulman Syndrome).
Hello, Chief Resident here.
Updated Key Findings: A 31-year-old postpartum primigravida with severe ADAMTS13 deficiency (6%) and negative inhibitor antibodies, confirmed by targeted sequencing to have biallelic ADAMTS13 mutations.
Differential Diagnoses:
1. Congenital Thrombotic Thrombocytopenic Purpura / Upshaw-Schulman Syndrome (USS): 95% – Unmasked during late pregnancy by physiological hemodynamic stress and transient infection, supported by <10% activity, absent inhibitor, and pathogenic mutations.
2. Acquired Immune-Mediated TTP: 3% – Ruled out by absent inhibitor antibodies (<0.4 U/mL) and confirmed genetic mutations.
3. Complement-Mediated aHUS: 2% – Ruled out by confirmed severe ADAMTS13 deficiency as the primary etiology.
Prioritized Next Steps:
1. Transition Strategy: Taper/stop immunosuppression (corticosteroids) as USS is non-immune; switch to regular prophylactic fresh frozen plasma (FFP) infusions or recombinant ADAMTS13 (rhADAMTS13 / Adzynma).
2. Postpartum Surveillance: Monitor CBC, LDH, and renal parameters to establish baseline ADAMTS13 levels post-acute episode.
3. Genetic Counseling & Family Screening: Counsel patient on recurrence risk in future pregnancies (requires early ADAMTS13 prophylaxis) and screen first-degree relatives.
4. Renal & Long-Term Care: Follow up on proteinuria and minor AKI to ensure complete microvascular recovery.
5. Patient Education: Educate on triggers (infections, stress, future pregnancy) that precipitate acute episodes.
Hello Attending Consultant here
Critique: Accurate confirmation of cTTP via activity <10%, absent inhibitor, and biallelic ADAMTS13 mutations; correctly de-escalates steroids. Under-emphasizes acute plasma product titration, recombinant ADAMTS13 access, and pregnancy-specific prophylaxis planning; omits mutation pathogenicity validation and family cascade testing urgency.
Top 3 DDx:
1. Congenital TTP (Upshaw-Schulman syndrome; pregnancy-unmasked)
2. Residual infection-triggered exacerbation of cTTP
3. Overlapping complement dysregulation (rare dual hit)
Specific points:
1. Continue daily PEX/FFP until PLT >150k and LDH normalizes ×2 days; then transition to prophylactic FFP or rhADAMTS13.
2. Discontinue corticosteroids immediately (non-immune).
3. Validate mutation pathogenicity (in silico + functional assay if available).
4. Genetic counseling + screen first-degree relatives for ADAMTS13 variants.
5. Future pregnancy: preemptive plasma/rhADAMTS13 from first trimester; serial ADAMTS13 monitoring.
6. Vaccinate and educate on infection triggers; baseline post-recovery ADAMTS13 activity.
7. Nephrology follow-up for residual proteinuria/AKI.
Hello, Expert Clinician here.
Best current unifying diagnosis: congenital TTP (Upshaw–Schulman syndrome), unmasked by pregnancy and an infection-like prodrome, presenting with IUFD and postpartum MAHA/AKI. Severe ADAMTS13 deficiency (6%), absent inhibitor, and biallelic pathogenic ADAMTS13 variants are diagnostic.
Top differentials:
- Acquired immune TTP: clinically similar, PLASMIC 6 fits, but negative inhibitor plus biallelic mutations exclude it.
- Complement-mediated aHUS: GI prodrome, AKI, proteinuria fit, but ADAMTS13 6% makes TTP definitive; dual-hit disease is uncommon.
- Infection-associated TMA/HELLP: plausible trigger or mimic, but does not explain inherited severe deficiency.
Key pivot: separating deficient enzyme activity from autoimmune inhibition. TTP was already likely; genetics converts “TTP” into a lifelong congenital diagnosis with pregnancy-specific implications.
Next move: continue plasma replacement until sustained platelet/hemolysis normalization, then transition to prophylactic FFP infusions or recombinant ADAMTS13 where available. Stop steroids. Arrange genetic counseling, family testing, trigger counseling, and future-pregnancy planning with early plasma prophylaxis.
Pearl: in suspected TTP, “inhibitor-negative” does not mean non-TTP—it should prompt evaluation for congenital ADAMTS13 deficiency.
Stage 5: Final Unifying Diagnosis & Clinical Management (Timestamp: Follow-up & Discharge)
Final Unifying Diagnosis: Congenital / Hereditary Thrombotic Thrombocytopenic Purpura (cTTP / Upshaw-Schulman Syndrome), unmasked by the pro-thrombotic, high endothelial burden of pregnancy.
Treatment Plan & Clinical Course:
- Acute Management: Complete clinical and hematologic response after 4 days of PEX, with platelet count rising to >250,000/µL, normalization of LDH, and resolution of AKI. Steroids tapered and stopped (immunosuppression non-beneficial in cTTP).
- Obstetric & Long-Term Plan: Counselled on autosomal recessive inheritance. Plan for prophylactic regular plasma infusions or recombinant ADAMTS13 replacement therapy during any future pregnancies to prevent recurrent fetal demise and maternal TMA.
Hello, Chief Resident here.
Updated Key Findings: Complete clinical and hematologic resolution (platelets >250,000/µL, normalized LDH/creatinine) following 4 days of plasma exchange in a primigravida post-IUFD. Confirmed by severe ADAMTS13 deficiency (6%), negative inhibitor, and biallelic pathogenic ADAMTS13 mutations.
Final Diagnosis:
- Congenital TTP / Upshaw-Schulman Syndrome (cTTP): 100% – Unmasked by the prothrombotic state of pregnancy; confirmed by severe enzyme deficiency without inhibitors and diagnostic genetic sequencing.
Management & Next Steps:
1. De-escalation: Corticosteroids discontinued; acute PEX completed. Establish baseline post-recovery ADAMTS13 activity.
2. Long-Term Prophylaxis: Maintenance therapy with regular prophylactic FFP infusions or recombinant ADAMTS13 (rhADAMTS13 / Adzynma).
3. Future Pregnancy Protocol: Preemptive prophylactic plasma/rhADAMTS13 replacement starting in the first trimester alongside serial ADAMTS13 monitoring to prevent recurrent fetal demise and maternal TMA.
4. Genetic Counseling & Cascade Screening: Counsel on autosomal recessive inheritance and offer genetic testing to first-degree relatives.
5. Patient Education: Educate on infection/stress triggers and prompt evaluation for future gastrointestinal or systemic symptoms.
Hello Attending Consultant here
Critique: Diagnosis airtight (activity 6%, inhibitor-neg, biallelic ADAMTS13 variants); response to PEX expected. Plan correctly stops steroids and addresses future pregnancy, but under-specifies rhADAMTS13 access/dosing, post-recovery baseline activity, cascade testing logistics, and residual proteinuria surveillance. Omits trigger prophylaxis details.
Top 3 DDx:
1. Congenital TTP (Upshaw-Schulman; pregnancy-unmasked)
2. Dual-hit cTTP + complement dysregulation (rare)
3. Resolved infection-triggered exacerbation of cTTP
Specific points:
1. Confirm sustained remission (PLT >150k, LDH nl ×48h) before discharge; establish nadir ADAMTS13 activity.
2. Prefer rhADAMTS13 (Adzynma) over FFP if available; dose to maintain activity >10–20%.
3. Immediate genetic counseling + cascade screen first-degree relatives.
4. Future pregnancy: start prophylaxis preconception/1st trimester; serial ADAMTS13 + fetal monitoring.
5. Nephrology f/u for residual proteinuria/AKI; baseline renal function.
6. Vaccinate + educate on infection/pregnancy triggers; emergency PEX protocol.
7. Document autosomal-recessive inheritance and IUFD recurrence risk without prophylaxis.
Hello, Expert Clinician here.
Best current unifying diagnosis: congenital TTP (Upshaw–Schulman syndrome) unmasked by pregnancy, presenting with late fetal demise and postpartum TMA. The rapid, complete response to plasma alone further supports enzyme replacement rather than immunologic disease.
Top differentials:
- Acquired immune TTP: clinically identical initially, but negative inhibitor and biallelic ADAMTS13 mutations exclude it.
- Complement-mediated aHUS: renal features fit, but ADAMTS13 6% and prompt plasma response make it secondary at most.
- Infection-triggered TMA: the GI/urinary prodrome may have precipitated the episode, but is not the underlying disease.
Key pivot: pregnancy revealed a lifelong enzyme deficiency that had remained clinically silent until endothelial/ADAMTS13 demand exceeded reserve.
Next move: discharge with a durable prophylaxis plan—scheduled FFP infusions or recombinant ADAMTS13, preferably rhADAMTS13 if available. Confirm durable remission, define baseline post-recovery ADAMTS13 activity, ensure genetic counseling/family testing, and establish preconception planning with early replacement therapy in any future pregnancy.
Pearl: first-lifetime TTP in pregnancy may be congenital, not acquired—negative inhibitor should trigger ADAMTS13 genetic testing.